Everything below concerns GLP-1 receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-27. Numbers and descriptions here follow the published literature rather than marketing material.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
=== Carbamic acids === Many substituted carbamic acids (RHNCOOH or RR′NCOOH), can be readily synthesized by bubbling carbon dioxide through solutions of the corresponding amine (RNH2 or RR′NH, respectively) in an appropriate solvent, such as DMSO or supercritical carbon dioxide. These carbamic acids are generally unstable at room temperature, reverting to the parent amine and carbon dioxide.
Miner's Bowery Theatre was a vaudeville or variety show theater opened by Senator Henry Clay Miner in 1878. The theater was known for its method of encouraging anyone to get on stage and perform on amateur nights, and for its method of removing bad performers from the stage by yanking them off with a wooden hook. Starting in the 1890s, a stage-prop shepherd's hook was used to pull bad performers bodily from the stage, after audience members shouted, "Give 'im the hook." The phrase, "Give him the hook" originated at Miners Bowery Theatre.
== Reception == The gravity gun was very well received by critics, who considered it one of the defining features of Half-Life 2's entertainment value. Planet Half-Life called the gravity gun "the next level in interactive gaming." Electronic Gaming Monthly described Half-Life 2's gravity gun as the "thinking man's death tool," which lets players "toy with gravity to kill foes with everyday objects." Call of Duty series military adviser Hank Keirsey stated that "the weapon is not very practical". He did, however, discuss its historical precedents, further stating that "The ancients learned very early how to use gravity to their advantage — but this usually involved rolling rocks down hills or pouring boiling oil down the castle walls. Those that failed to respect gravity suffered." Andy Kelly of GamesRadar+ called the Gravity Gun one way that Half-Life 2 changed gaming forever, citing its usage as a weapon in the zombie-infested town of Ravenholm as a particular high point that caused numerous subsequent games to incorporate physics manipulation devices into their gameplay. Christopher Livingston of PC Gamer described the moment the Gravity Gun turned blue as one of the great moments in PC gaming, calling it a "glorious, cathartic moment".
Bissy tea, a beverage made from kola nuts popular in Jamaica Cacao bean tea, which contains theobromine and a small amount of caffeine. Coffee-leaf tea, coffee fruit tea, and coffee blossom tea are herbal teas made using the leaves, fruits and flowers of the coffee plant Guarana tea, a beverage made from guarana seeds containing more than three times the caffeine of coffee Guayusa tea, made from the caffeinated leaves of the ilex guayusa holly, native to the Amazon rainforest Mate, a South American caffeinated tea made from the holly yerba mate (Ilex paraguariensis) Yaupon tea, made from caffeinated leaves of the yaupon holly native to North America Tea made from Ilex cassine (dahoon holly or cassena), which has less caffeine than yaupon, but more theobromine
Sources: en.wikipedia.org
=== Iranian plan === Cessation of the war on Iraq, Lebanon, and Yemen Cessation of the war in Iran with no time limit Ending all conflicts in the region Reopening the Strait of Hormuz Establishing a protocol and conditions to ensure freedom and security of navigation in the Strait Full payment of war reparations to Iran Lifting sanctions on Iran Release of the Iranian frozen assets held by the United States Iran commits to not seeking possession of any nuclear weapons Immediate ceasefire on all fronts upon the ceasefire announcement Further complicating matters, Iran released several different version of the plan, with small differences, and differences between the Persian and English versions.
=== Thermoregulation === Blood circulation transports heat throughout the body, and adjustments to this flow are an important part of thermoregulation. Increasing blood flow to the surface (e.g., during warm weather or strenuous exercise) causes warmer skin, resulting in faster heat loss. In contrast, when the external temperature is low, blood flow to the extremities and surface of the skin is reduced to prevent heat loss and is circulated to the important organs of the body, preferentially.
Nathaniel Kayne Finley (1999–2017), born to Curtis Lee, a former member of the U.S. Armed Forces and Kirsten Darlene Finley. Finley was a member of USA Swimming through Northern Kentucky Clippers and Daytona Beach Speed swimming clubs. Despite being diagnosed with DIPG in late 2016, Finley choose to attend LSU as a freshman in fall 2017, majoring in the College of Agriculture, Animal Sciences with aspirations of becoming a veterinarian. Prior to his death, Finley signed an advance directive, ensuring that his tumor could be donated for scientific research, and established Cannonballs for Kayne, a DIPG research foundation. Kevin Lobello (2015–2025), a boy who became the first person to watch A Minecraft Movie in a special screening along with actor Sebastian Hansen. He was diagnosed in 2023 and died 11 days after the screening on March 12, 2025. Kelley Mack (1992–2025), an actress best known for her role in season 9 of The Walking Dead. She was diagnosed in January 2025 and died August 2, 2025.
Full fat cottage cheese is 78% water, 12% protein, 5% carbohydrates, and 4% fat (table). In a reference amount of 100 g (3.5 oz), full fat cottage cheese supplies 103 calories of food energy, and is a rich source (20% or more of the Daily Value, DV) of vitamin B12 (28% DV) and a moderate source of phosphorus and sodium (12-15% DV, table). Cottage cheese is safe to eat during pregnancy, unlike some cheese products that are not recommended. Other than supplying nutrients, there is little evidence that consuming cottage cheese provides any direct health effects.
== Clinical use == European Association of Urology (EAU) guidelines recognise that PSMA can provide accurate staging, however there is a lack of outcome data to inform further management. The American Society of Clinical Oncology (ASCO) guidelines for imaging of advanced prostate cancer also recommend PSMA imaging (among other PET radiopharmaceuticals), while acknowledging that these are not FDA approved and therefore limited to a clinical trial or other controlled research setting. Although PSMA PET imaging has shown clear superiority over conventional CT and bone scans for detecting prostate cancer, comparative studies assessing different PSMA ligands, such as 68Ga-PSMA-11 and 18F-DCFPyL, remain limited. A 2024 overview of reviews published in Seminars of Nuclear Medicine concluded that while evidence gaps remain for some outcomes and most systematic reviews are at high or unclear risk of bias, the evidence base is broadly supportive of 18F PSMA PET/CT in patients with high-risk prostate cancer or biochemical recurrence
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.